Supplementary Figure 10 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy

Sarah Porte; Alexandra Audemard‐Verger; Christian Wu; Aurélie Durand; Théo Level; Léa Giraud; Amélie Lombès; Mathieu Germain; Rémi Pierre; Benjamin Saintpierre; Mireille Lambert; Cédric Auffray; Carole Peyssonnaux; François Goldwasser; Sophie Vaulont; Marie‐Clotilde Alves‐Guerra; Renaud Dentin; Bruno Lucas; Bruno Martin

doi:10.1158/2326-6066.26926347

Abstract

Body ferritin level does not modulate plasma concentrations of IL-6, IL-9, IL-10, IL-17A, IL-33 or TNFα following anti-PD1 immunotherapy in cancer patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Porte et al. (2024) studied this question.

synapsesocial.com/papers/68e598d9b6db6435875331d0 https://doi.org/10.1158/2326-6066.26926347

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 10 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy

Abstract

Discussion

Cite This Study

Supplementary Figure 10 from Iron Boosts Antitumor Type 1 T-cell Responses and Anti-PD1 Immunotherapy

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers